Dr. Paul F. Riska, MD

Dr. Riska practices at Montefiore Einstein Hospital-Moses Campus in Bronx, New York, part of Montefiore Einstein.

Dr. Riska's NPI, 1245274364, was assigned on June 16, 2006. Dr. Riska graduated from Duke University School Of Medicine in 1989. Dr. Riska holds New York license 1827451.

Dr. Riska's primary practice is Montefiore Einstein Hospital-Moses Campus, at 111 East 210th Street, Bronx, NY 10467 in Bronx County. The practice phone is (718) 920-4321.

Dr. Riska's primary practice is Montefiore Einstein Hospital-Moses Campus in Bronx, New York, part of Montefiore Einstein. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Dr. Riska to 1 more school health center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Riska practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Riska's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Riska is board certified in infectious disease by the American Board of Internal Medicine. Dr. Riska is licensed in New York.

Dmand AI lists acute skin infection, hiv/aids, joint or bone infection, pneumonia and UTI among the conditions Dr. Riska treats.

CMS data shows 273 Medicare services from Dr. Riska across 7 procedure codes in 2024, for 134 Medicare patients. Medicare paid $21,348 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 134 Medicare patients who saw Dr. Riska in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 77% are also on Medicaid. Their average risk score is 4.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Riska's median patient age at 65, with 47% women.

In 2024, Dr. Riska wrote 4,770 Medicare Part D claims for 115 patients. 71% of them were for generic drugs. CMS names the drug for 4,211 of them, across 115 drugs with 11 or more claims each, at $2,880,537 in total drug cost. In 2023, CMS named 4,425 claims across 126 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Riska for performance year 2024, reported as part of a group. CMS lists Dr. Riska as offering telehealth.

Dmand AI links 31 papers to Dr. Riska, published from 2007 to 2024. 2011 was the busiest year, with 2. The most frequent topics are Mycobacterium tuberculosis, Microbial Sensitivity Tests and Luciferases. Dr. Riska has published most often in J Clin Microbiol. Dr. Riska's most frequent co-authors are John P. Bedolla, MD, Liise-Anne Pirofski, MD and Elizabeth Knackmuhs Revere, MD.

Dmand AI links Dr. Riska to 4 clinical trials. Conditions studied include Bacteremia, Clostridium Infections and Diarrhea.

CMS Open Payments shows 118 general payments to Dr. Riska from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 69% of the total. Gilead Sciences, Inc. paid the most, $4,658.

Dr. Riska graduated from Duke University School Of Medicine in 1989.

Dr. Riska is in network with 17 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.